Contrasting Quanterix (NASDAQ:QTRX) & Allurion Technologies (NYSE:ALUR)

Quanterix (NASDAQ:QTRX) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

86.5% of Quanterix shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Quanterix has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500.

Profitability

This table compares Quanterix and Allurion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quanterix	-71.86%	-23.92%	-17.66%
Allurion Technologies	-199.96%	N/A	-77.13%

Earnings and Valuation

This table compares Quanterix and Allurion Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90 million	1.15	-$107.15 million	($2.36)	-1.44
Allurion Technologies	$17.21 million	0.51	-$7.20 million	($2.03)	-0.29

Allurion Technologies has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Quanterix and Allurion Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1	2	0	0	1.67
Allurion Technologies	1	1	1	0	2.00

Quanterix currently has a consensus price target of $4.00, indicating a potential upside of 17.99%. Allurion Technologies has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Quanterix.

Summary

Allurion Technologies beats Quanterix on 8 of the 14 factors compared between the two stocks.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.